

Aimmune Therapeutics, Inc.  
Form 8-K  
February 26, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 21, 2018**

**AIMMUNE THERAPEUTICS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**001-37519**  
**(Commission**

**File Number)**  
**8000 Marina Blvd, Suite 300**

**45-2748244**  
**(IRS Employer**

**Identification Number)**

Edgar Filing: Aimmune Therapeutics, Inc. - Form 8-K

**Brisbane, CA 94005**

**(Address of principal executive offices, including Zip Code)**

**Registrant's telephone number, including area code: (650) 614-5220**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

### Item 8.01 Other Events.

On February 21, 2018, Aimmune Therapeutics, Inc. (the Company) entered into an underwriting agreement (the Underwriting Agreement) with Merrill, Lynch, Pierce, Fenner & Smith Incorporated, Incorporated, as representative (the Representative) of the several underwriters named therein (collectively, the Underwriters), pursuant to which the Company agreed to issue and sell 5,500,000 shares (the Shares) of its common stock, par value \$0.0001 per share (Common Stock), to the Underwriters (the Offering). The Shares were sold at a public offering price of \$32.00 per Share, and were purchased by the Underwriters from the Company at a price of \$30.08 per Share. Under the terms of the Underwriting Agreement, the Company granted the Underwriters the option, for 30 days, to purchase up to 825,000 additional shares of Common Stock at the public offering price.

The Offering was made under a prospectus supplement and related prospectus filed with the Securities and Exchange Commission pursuant to the Company's effective shelf registration statement on Form S-3 (Registration No. 333-222333).

On February 26, 2018, the Offering closed and the Company completed the sale and issuance of an aggregate of 5,500,000 shares of Common Stock. The Company received net proceeds from the Offering of approximately \$164.2 million, after deducting the Underwriters' discounts and commissions and estimated offering expenses payable by the Company.

Pursuant to the Underwriting Agreement, the Company agreed to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended, or to contribute to payments that the Underwriters may be required to make because of such liabilities. The Company and the Company's directors and executive officers (and certain of their affiliated stockholders) also agreed not to sell or transfer any Common Stock for 60 days after February 21, 2018 without first obtaining the written consent of the Representative on behalf of the Underwriters, subject to certain exceptions as described in the prospectus supplement.

A copy of the Underwriting Agreement is attached as Exhibit 1.1 hereto and is incorporated herein by reference. The foregoing descriptions of the Underwriting Agreement and lock-up arrangements do not purport to be complete and are qualified in their entirety by reference to such exhibit.

A copy of the opinion of Latham & Watkins LLP relating to the validity of the securities issued in the Offering is filed herewith as Exhibit 5.1.

### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
1.1	<u>Underwriting Agreement, dated as of February 21, 2018, among Aimmune Therapeutics, Inc. and Merrill, Lynch, Pierce, Fenner &amp; Smith Incorporated, as representative of the underwriters named therein.</u>
5.1	<u>Opinion of Latham &amp; Watkins LLP.</u>
23.1	<u>Consent of Latham &amp; Watkins LLP (included in Exhibit 5.1).</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AIMMUNE THERAPEUTICS, INC.**

Date: February 26, 2018

By: /s/ Douglas T. Sheehy  
Douglas T. Sheehy  
General Counsel & Corporate Secretary